The excess risk of patient-reported urinary incontinence according to the mean dose model based on absorbed dose (solid black) and fractionation-corrected dose into equivalent 2-Gy fractions using the Linear-quadratic model with a/b=3 for late effects (solid grey). Dotted lines indicate 68% confidence intervals. Conclusions: Efforts to maintain the mean absorbed urinary bladder dose below 29 Gy (mean fractionation-corrected dose of 22 Gy 3 ) in prostate-cancer treatments with EBRT may keep the prevalence of patient-reported urinary incontinence below 10%. Both dose representations provide similar results for the clinically relevant range of dose values. Purpose/Objective: In carbon ion radiotherapy, the increased relative biological effectiveness (RBE) has to be modeled to arrive at the biologically effective dose. In this study, the RBE of carbon ions was measured in the spinal cord and the results were compared to predictions of the local effect model (LEM) as well as to clinical data on normal tissue reactions. Materials and Methods: The cranial part of the spinal cord of rats was irradiated with 1, 2, 6 or 18 fractions (Fx) of photons or carbon ions, respectively [1]. Carbon ion irradiations were performed in the plateau region (13 keV/mm) or in the middle of a 1 cm spread-out Bragg peak (SOBP, 125 keV/mm). Biological endpoint was the onset of paresis grade II within 10 months after irradiation. Dose response curves were measured and RBEs were calculated based on D 50 (dose at 50% complication probability). In addition α/β-values were determined. Results: The RBE-values were 1.44±0.08, 1.37±0.05, 1.33±0.02 and 1.42±0.02 for the plateau-and 1.77±0.06, 2.17±0.06, 2.97±0.05, and 5.04±0.08 for the peak-irradiations (1, 2, 6, and 18 Fx, respectively). The respective predictions by the clinically applied local effect model (LEM I) were 1.14, 1.19, 1.37, and 1.72 for the plateau-and 1.28, 1.61, 2.35, and 3.80 for the peak irradiations, respectively. The α/β-values were 2.8±0.4 Gy for photons, 2.1±0.4 Gy for the plateau and 37.0±5.3 Gy for the peak-irradiations, respectively.
Purpose/Objective: In carbon ion radiotherapy, the increased relative biological effectiveness (RBE) has to be modeled to arrive at the biologically effective dose. In this study, the RBE of carbon ions was measured in the spinal cord and the results were compared to predictions of the local effect model (LEM) as well as to clinical data on normal tissue reactions. Materials and Methods: The cranial part of the spinal cord of rats was irradiated with 1, 2, 6 or 18 fractions (Fx) of photons or carbon ions, respectively [1] . Carbon ion irradiations were performed in the plateau region (13 keV/mm) or in the middle of a 1 cm spread-out Bragg peak (SOBP, 125 keV/mm). Biological endpoint was the onset of paresis grade II within 10 months after irradiation. Dose response curves were measured and RBEs were calculated based on D 50 (dose at 50% complication probability). In addition α/β-values were determined. Results: The RBE-values were 1.44±0.08, 1.37±0.05, 1.33±0.02 and 1.42±0.02 for the plateau-and 1.77±0.06, 2.17±0.06, 2.97±0.05, and 5.04±0.08 for the peak-irradiations (1, 2, 6, and 18 Fx, respectively). The respective predictions by the clinically applied local effect model (LEM I) were 1.14, 1.19, 1.37, and 1.72 for the plateau-and 1.28, 1.61, 2.35, and 3.80 for the peak irradiations, respectively. The α/β-values were 2.8±0.4 Gy for photons, 2.1±0.4 Gy for the plateau and 37.0±5.3 Gy for the peak-irradiations, respectively.
Conclusions:
Carbon ion irradiations of the spinal cord are significantly more effective in the Bragg-peak than in the plateau region. A significant fractionation effect was found only for the plateau. The clinically applied LEM-version correctly describes the main features although it generally underestimated the RBE in the Bragg-peak by about 25% ( fig. 1) . In contrast, a retrospective clinical study determined the biologically equivalent tolerance dose for 5% probability of MRI-detected temporal lobe reactions (D 5 ) to be 68.8±3.3 GyE [2] . This value complies well with clinical experience from photon therapy and hence, there is no indication for a significant underestimation of the RBE in patients. Meanwhile, improved versions of the LEM (LEM II-IV) are available [3, 4] , which show good agreement with the measured RBE-values for the peak region. To clarify the relation between experimental, clinical and calculated RBEs, the clinical data have to be reanalyzed using LEM IV. Further work is ongoing to systematically determine RBE and α/β-values at several positions in an extended SOBP corresponding to different LET-values. Purpose/Objective: Post radiation therapy (RT) chronic otitis media (COM) has been implicated with incidence of sensory neural hearing loss (SNHL) in head & neck cancer (HNCa) patients. The goal of this study is to examine the association and evaluate the effect of post-RT COM on the dose parameters associated with post-RT SNHL in head and neck cancer (HNCa) patients receiving RT ± chemotherapy (chemo) using logistic modeling. Materials and Methods: Radiation oncology and otolaryngology records of 395 HNCa patients who received RT±Chemo were retrospectively reviewed to code incidence of post-RT COM and SNHL using air & bone conduction thresholds for high frequency hearing at 4 kHz. The criteria for SNHL was 10 dB increase in hearing threshold with respect to baseline evaluation. Median follow up was 5.7 Years (range: 0.5-30 years). Mean doses received by the middle ear and cochlea were estimated by treatment plan evaluation and used for analysis. A Fisher's exact test used to determine association between post-RT COM and SNHL. A logistic function was used to describe the dose response for incidence of SNHL for patients treated with RT only and those with Chemo+RT. In each group the model was fitted first to all patients (including those with post RT COM) treated with the specific modality (RT only or RT+Chemo) and then to the subset of the patients treated with that modality who did not have occurrence of post-RT COM. Maximum likelihood method was used to optimize the fit. Results: Post-RT COM was observed in 31.5% patients. Fisher's exact test indicated that post-RT COM was significant in the incidence of SNHL (p <0.001). The estimated TD 5 & TD 10 for RT Only group were 34.3 Gy, 41.9 Gy when all the patients were included and those for subset of patients without post-RT COM were 37.1 Gy, 44.7 Gy. Those for Chemo+RT group were 29.8 Gy, 37.4 Gy when all patients included and those for subset of patients without post-RT COM were 38.1 Gy,
